🇺🇸 FDA
Patent

US 7829693

Compositions and methods for inhibiting expression of a target gene

granted A61KA61K38/00A61P

Quick answer

US patent 7829693 (Compositions and methods for inhibiting expression of a target gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Nov 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/00, A61P, A61P25/28, A61P31/12